Advertisement

Topics

Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug - Biotech, Pharma and Life Science Channel

09:34 EDT 15th August 2018 | BioPortfolio

Brilinta

Brilinta - ticagrelor, AstraZeneca's new heart drug is a blood-thinning medicine designed to prevent dangerous blood clots in patients with serious chest pain or previous heart attacks. It reduces the clumping of blood particles, called platelets, that promote clotting.

Analysts believe that peak sales of Brilinta could reach $2bn or more, but Brilinta will face stiff competition in the blood-thinning market, notably from Plavix.

What is BRILINTA?

BRILINTA is a type of prescription antiplatelet medication for people who have had a recent heart attack or severe chest pain that happened because their heart wasn't getting enough oxygen and who are being treated with medicines or procedures to open blocked arteries in the heart. BRILINTA is used with aspirin to stop platelets from sticking together and forming a blood clot that could block blood flow to the heart and cause another, possibly fatal, heart attack. Platelets are small cells in the blood that help with normal blood clotting.

Why BRILINTA?

BRILINTA used with aspirin lowers your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. These can be fatal. In fact, in a large clinical study BRILINTA was even better than Plavix® (clopidogrel bisulfate) tablets at lowering your chances of having another heart attack.

Key documents: Patient Prescribing Information ~ Medication Guide

BRILINTA is a trademark of the AstraZeneca group of companies.

Plavix® is a registered trademark of sanofi-aventis.

News Articles [4 Associated News Articles listed on BioPortfolio]

SMS Pharmaceuticals Ltd SMSPHARMA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 25042018] Prices from USD $250

SummarySMS Pharmaceuticals Ltd SMS Pharma is a manufacturer of active pharmaceutical ingredients APIs and intermediates that develops offers antifungal, antiulcer, antimigraine, antihypersensitive, an...

PhaseBio Announces Completion of Dosing in First Cohort of Phase 1 Clinical Trial of PB2452, a Reversal Agent for Ticagrelor

MALVERN, Pa., April 05, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announ...

Kopran Ltd KOPRAN Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryKopran Ltd Kopran is a pharmaceutical company that manufactures finished dosage forms and active pharmaceutical ingredients. The company's finished dosage form includes tablets, dry powders for...

SMS Pharmaceuticals Ltd SMSPHARMA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 19022018] Prices from USD $250

SummarySMS Pharmaceuticals Ltd SMS Pharma is a manufacturer of active pharmaceutical ingredients APIs and intermediates that develops offers antifungal, antiulcer, antimigraine, antihypersensitive, an...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [148 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Safety of Low Dose Ticagrelor in Patients With Unstable Angina Pectoris After Coronary Stent Implantation

The study is to evaluate efficacy and safety of low dose of ticagrelor therapy for Chinese patients treated with non-urgent coronary stent implantation, to examine whether lower dose ticag...

Ticagrelor and Clopidogrel on Platelet Aggregation in Clopidogrel Resistance's Patients With CHD

The study sought to observe the effects of optimal dose of ticagrelor(90 mg qd)ticagrelor and double standard-dose clopidogrel on platelet reactivity in coronary heart disease patients ...

Effect of Diabetes and Hepatic Enzymes Mutation on Clopidogrel VS Ticagrelor Actity in MI Patients Undergoing Primary PCI

In this study the combined effect of diabetes mellitus and cyp2c19 polymorphism on platelet aggregation inhibitory activity of the highest traditionally used loading dose 600 mg clopidogre...

Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease

The purpose of the study is to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Paediatric Patients with Sickle Cell Disease

The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease

The study is to further exploring the optimal switching strategy by evaluating the pharmacodynamic responses as well as adverse events in patients with complexity of coronary artery diseas...

Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome

The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CAB...

CHAOS Registry Study

INTRODUCTION: About 6-8% of patients undergoing PCI have an indication for long-term oral anticoagulants (OACs) due to various conditions such as atrial fibrillation (AF), mechanical heart...

Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction

Multicenter randomized double blind trial comparing intravenous cangrelor and oral ticagrelor in patients with acute myocardial infarction complicated by initial cardiogenic shock and trea...

Central Apnea in Patients Receiving Ticagrelor

all patients with a left ventricular ejection fraction superior or equal to 50% less than 2 years after an acute coronary event and receiving ticagrelor will undergo a sleep polygraphy

Platelet Reactivity And Clinical ThrombotIC Events Study

Platelet function testing has been considered for DAPT strategy adjustments to reduce the patient's risk of ischemia and bleeding. Although several previous RCT studies did not find any be...

PubMed Articles [42 Associated PubMed Articles listed on BioPortfolio]

Use of ticagrelor alongside fibrinolytic therapy in patients with ST-segment elevation myocardial infarction: practical perspectives based on data from the TREAT study.

Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method in patients with ST-segment elevation myocardial infarction (STEMI). In patients with STEMI who cannot undergo time...

Quantification of unbound concentration of ticagrelor in plasma as a proof of mechanism biomarker of the reversal agent, MEDI2452.

Ticagrelor, a P2Y12 antagonist, is approved for prevention of thromboembolic events. MEDI2452 is a potential reversal agent for ticagrelor and ticagrelor active metabolite (TAM). The total plasma expo...

Comparison of the Effects of Ticagrelor and Clopidogrel on Inflammatory Factors, Vascular Endothelium Functions and Short-Term Prognosis in Patients with Acute ST-Segment Elevation Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention: a Pilot Study.

Acute ST-segment elevation of myocardial infarction (STEMI) is the most severe type of acute coronary syndrome (ACS). Particular attention has been focused on studying the pathogenesis of STEMI, and h...

Comparison of Systematic Ticagrelor-Based Dual Antiplatelet Therapy to Selective Triple Antithrombotic Therapy for Left Ventricle Dysfunction Following Anterior STEMI.

Antithrombotic management of STEMI patients with apical dysfunction, but without demonstrable thrombus, is controversial. Triple antithrombotic therapy (TATT, defined as the addition of oral anticoagu...

Fentanyl Delays the Platelet Inhibition Effects of Oral Ticagrelor: Full Report of the PACIFY Randomized Clinical Trial.

Morphine delays oral P2Y platelet inhibitor absorption and is associated with adverse outcomes after myocardial infarction. Consequently, many physicians and first responders are now considering fenta...

The effect of prehospital P2Y12 receptor inhibition in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: the ATLANTIC-Elderly analysis.

To examine the main results of the ATLANTIC trial in patients with ST-elevation myocardial infarction (STEMI), randomized to pre- versus in-hospital ticagrelor according to age.

Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials.

Dual antiplatelet therapy with aspirin and clopidogrel are recommended as adjuncts to fibrinolytic-treated patients with ST-elevation myocardial infarction (STEMI). However, the role of switching to t...

Lethal cerebral hemorrhage after ticagrelor intoxication: a specific antidote is urgently needed.

Ticagrelor is a direct and reversible competitive antagonist of the P2Y12 receptor and inhibits platelet activation. Although adverse bleeding is common, fatal intoxication has never been documented.

Ticagrelor Use in Acute Myocardial Infarction: Insights From the National Cardiovascular Data Registry.

Ticagrelor is a P2Y receptor inhibitor with superior clinical efficacy compared with clopidogrel. However, it is associated with reduced efficacy when combined with a high-dose aspirin.

Pharmacodynamic Effects of a 6-Hour Regimen of Enoxaparin in Patients Undergoing Primary Percutaneous Coronary Intervention (PENNY PCI Study).

Delayed onset of action of oral P2Y inhibitors in ST-elevation myocardial infarction (STEMI) patients may increase the risk of acute stent thrombosis. Available parenteral anti-thrombotic strategies, ...

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

review and buy Brilinta (TM) - ticagrelor, AstraZeneca's new heart drug market research data and corporate reports here

Channels Quicklinks